Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Biome Australia Ltd ( (AU:BIO) ) is now available.
Biome Australia Limited has announced that its Q1 FY26 sales revenue is expected to exceed $5.5 million, setting a new quarterly revenue record and surpassing the previous record of $5.0 million achieved in Q4 FY25. This growth reflects the company’s strong market position and the increasing demand for its innovative probiotic products, potentially enhancing its industry standing and offering positive implications for stakeholders.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.95 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
More about Biome Australia Ltd
Biome Australia Limited is a microbiome health company that develops, licenses, commercializes, and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines. The company aims to improve health outcomes and quality of life, making its products accessible globally. Founded in 2018, Biome collaborates with leading organizations in microbiome research to produce unique probiotic products with advanced delivery technologies, marketed under the brand Activated Probiotics. These products are supported by clinical research and are distributed through practitioner-only channels to educate health professionals on gut microbiota’s health effects.
Average Trading Volume: 404,517
Technical Sentiment Signal: Buy
For detailed information about BIO stock, go to TipRanks’ Stock Analysis page.